Scott R S, Johnson R J, Kowal H, Krishnamsetty R M, Story K, Clay L
Int J Radiat Oncol Biol Phys. 1983 Sep;9(9):1327-33. doi: 10.1016/0360-3016(83)90264-x.
Facilities for regional tumor hyperthermia has been in use at RPMI since 1976, and have been routinely used to treat patients according to protocol since 1977. Hyperthermia delivery has been exclusively by microwave using 434 MHz, 915 MHz and 2450 MHz. Greatest success at reaching tumor temperatures of 43-44 degrees C with minimal skin heating was obtained using 915 MHz. The majority of the patients were treated with this frequency. Approximately 125 patients have been treated and 70 have achieved completion of therapy and follow-up. Follow-up has been at least one month and several patients have been followed for one to two years. Initially, for entry into the hyperthermia protocol, patients were required to have three or more lesions. One lesion on each patient was treated with 800 rad fractions repeated three times on a 72 hour schedule. The second lesion was treated with 700 rad fractions and the third with 500 rad plus hyperthermia on the same schedule. Twelve patients with multiple melanoma lesions completed this study. One of 12 patients showed no response to the combination of hyperthermia plus radiotherapy, while four showed no response to radiotherapy alone. Of eight patients who survived three months, all lesions treated by hyperthermia plus radiotherapy responded completely, while only five lesions treated by radiotherapy alone so responded. In a second study, 58 patients with superficial tumors were treated by a protocol where hyperthermia was added to optimal conventional radiotherapy. Of the total, 43 patients had complete tumor response at follow-up varying from one month to 18 months. A subgroup of 24 of these patients had two lesions, one of which was treated with hyperthermia in addition to radiotherapy while the other served as control, receiving radiotherapy only. Nineteen lesions demonstrated complete response to hyperthermia plus radiotherapy, while only 14 of the controls had complete response. None of the lesions treated with hyperthermia responded less well than those treated by radiotherapy alone. Morbidity, as measured by skin reaction, was rarely increased in the heated field.
自1976年以来,罗斯韦尔帕克纪念研究所(RPMI)就一直在使用区域肿瘤热疗设备,自1977年起便按照方案常规用于治疗患者。热疗仅通过使用434兆赫、915兆赫和2450兆赫的微波进行。使用915兆赫时,在使肿瘤温度达到43 - 44摄氏度且皮肤受热最小方面取得了最大成功。大多数患者接受的就是这个频率的治疗。大约125名患者接受了治疗,其中70名已完成治疗及随访。随访时间至少为一个月,有几名患者已被随访一至两年。最初,为了进入热疗方案,要求患者有三个或更多病灶。每位患者的一个病灶接受800拉德分次照射,按72小时的时间表重复三次。第二个病灶接受700拉德分次照射,第三个病灶接受500拉德加相同时间表的热疗。12名患有多发性黑色素瘤病灶的患者完成了这项研究。12名患者中有1名对热疗加放疗的联合治疗无反应,而有4名对单纯放疗无反应。在存活三个月的8名患者中,所有接受热疗加放疗治疗的病灶均完全缓解,而仅接受放疗治疗的病灶只有5个完全缓解。在第二项研究中,58名浅表肿瘤患者按照将热疗添加到最佳常规放疗中的方案进行治疗。总共43名患者在随访(时间从一个月到18个月不等)时肿瘤完全缓解。这些患者中有一个24人的亚组有两个病灶,其中一个病灶除放疗外还接受热疗,另一个作为对照,仅接受放疗。19个病灶对热疗加放疗表现出完全缓解,而对照组中只有14个病灶完全缓解。接受热疗治疗的病灶,其反应情况不比单纯接受放疗治疗的病灶差。以皮肤反应衡量的发病率在受热区域很少增加。